Search Results
Jun 15, 2026, 12:31 ET EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight
SMT112) is a novel PD-1/VEGF bispecific antibody and the first agent of its kind to advance into Phase III clinical testing. Developed using the company's proprietary Tetrabody platform, the therapy is designed to simultaneously inhibit PD-1 interactions with PD-L1 and PD-L2 while also blocking VEGF
More news about: DelveInsight Business Research, LLP
Jun 15, 2026, 02:52 ET Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy
represents 10-20% of cases. The trial enrolls patients across multiple treatment lines from treatment-naïve to heavily pretreated, and includes diverse PD-L1 expression levels. Breast cancer remains the most common cancer among women worldwide, with an estimated 2.3 million new cases diagnosed annually.
More news about: Akeso, Inc.
Jun 12, 2026, 08:00 ET Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
trial was conducted in patients with SCLC, whose disease has progressed following prior platinum-containing chemotherapy with or without anti-PD-1 or anti-PD-L1 agents. The LAGOON trial enrolled 724 patients from more than 200 sites globally, including in the U.S., Canada and Europe. The trial is sponsored
More news about: Jazz Pharmaceuticals plc
Jun 11, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
combination with cemiplimab (PD-1 inhibitor) as a first-line treatment for patients with unresectable locally advanced or metastatic melanoma" "did not each statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy."On
More news about: Pomerantz LLP
Jun 11, 2026, 09:10 ET Aspen Neuroscience Appoints Jeff Boerneke as General Counsel and Secretary
neurodegenerative diseases of high unmet need including Parkinson's disease (PD). Its lead product candidate is sasineprocel (ANPD001), the most advanced autologous investigational cell therapy in the United States for treating PD.About Sasineprocel Sasineprocel is a single-dose,
More news about: Aspen Neuroscience, Inc.
Jun 11, 2026, 07:00 ET Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026
evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developed by AstraZeneca pursuant to an exclusive license
More news about: Compugen Ltd.
Jun 11, 2026, 02:20 ET CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
patients have PD-L1 ≤1% (low/negative), and 1 patient has PD-L1 ≤5% (low expression); median age is 70 years;ORR was 75% and DCR was 100%; among PD-L1-negative patients, ORR reached 100%;Particularly noteworthy:A 100% response rate was observed among PD-L1-negative
More news about: CStone Pharmaceuticals
Jun 11, 2026, 01:00 ET Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
respond well to immune checkpoint inhibitors (ICIs) such as PD-1 or PD-L1 inhibitors. For patients with endometrial cancer without MMR deficiency (pMMR), the addition of PARP inhibitors in maintenance to ICIs may further enhance the benefit of ICIs. PD-1 inhibitors may retain activity when combined with a
More news about: Roche
Jun 11, 2026, 01:00 ET Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
respond well to immune checkpoint inhibitors (ICIs) such as PD-1 or PD-L1 inhibitors. For patients with endometrial cancer without MMR deficiency (pMMR), the addition of PARP inhibitors in maintenance to ICIs may further enhance the benefit of ICIs. PD-1 inhibitors may retain activity when combined with a
More news about: Roche
Jun 10, 2026, 16:15 ET Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update
determine the appropriate dosing in participants with solid tumors whose disease is stable or progressing while on a treatment that includes the anti-PD-1 agents, Keytruda® or Opdivo®.Other Recent DevelopmentsDuring fiscal 2026, we strengthened our intellectual
More news about: Aethlon Medical, Inc.
Jun 10, 2026, 09:16 ET HkeyBio Launches "NHP Fast-PoC" Program to Deliver Low-Cost Cyno PK/PD and Developability Data Amid Rising NHP Prices
development."The program offers flexible service modules covering pharmacokinetic profiling, target engagement assessment, receptor occupancy analysis, PK/PD correlation evaluation and early developability confirmation. It is particularly applicable to siRNA and biologics targeting immune pathways such as
More news about: HKeyBio
Jun 10, 2026, 02:22 ET Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
wide range of immune disorders, neurology and potentially endocrine conditions.3 The presentation will describe the inhibitory effect and PK/PD profile of Lu AG22515, including effects on membrane-bound and soluble CD40L, B-cell activation and differentiation, proinflammatory cytokine production
More news about: H. Lundbeck A/S
Jun 10, 2026, 02:19 ET Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
wide range of immune disorders, neurology and potentially endocrine conditions.3 The presentation will describe the inhibitory effect and PK/PD profile of Lu AG22515, including effects on membrane-bound and soluble CD40L, B-cell activation and differentiation, proinflammatory cytokine production
More news about: H. Lundbeck A/S
Jun 09, 2026, 21:00 ET Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using
More news about: Antengene Corporation Limited
Jun 09, 2026, 09:00 ET Parkinson's Foundation & WHO Foundation Announce Partnership to Advance Global Care
Disease, which engaged multidisciplinary global Parkinson's and health experts, identified global PD needs for possible impact through collective support and collaboration. Discussions exploring PD care and impact found a substantial global treatment gap for neurological disorders, disproportionately
More news about: Parkinson's Foundation
Jun 08, 2026, 14:41 ET Michael J. Fox Foundation Recognized for Excellence in Video Storytelling with Multiple Telly Awards
television and video industry, further reinforcing MJFF's commitment to producing high-quality, credible and empathic content for the Parkinson's disease (PD) community. In its 47th awards season, the Telly competition selected outstanding videos across advertising, television and production companies and
More news about: The Michael J. Fox Foundation for Parkinson's Research
Jun 08, 2026, 08:20 ET GEEKOM Launches the New GeekBook M16, Redefining the $800 High-Performance Productivity Laptop Segment
power management system, the laptop supports up to 24 hours of Wi-Fi usage and approximately 20 hours of local video playback. It also supports 100W PD GaN fast charging, with a 10-minute charge delivering efficient productivity on the go.For display and design,
More news about: GEEKOM
Jun 08, 2026, 08:20 ET GEEKOM Launches the New GeekBook M16, Redefining the $800 High-Performance Productivity Laptop Segment
power management system, the laptop supports up to 24 hours of Wi-Fi usage and approximately 20 hours of local video playback. It also supports 100W PD GaN fast charging, with a 10-minute charge delivering efficient productivity on the go.For display and design,
More news about: GEEKOM
Jun 08, 2026, 08:20 ET GEEKOM bringt das neue GeekBook M16 auf den Markt und setzt damit neue Maßstäbe im Segment der leistungsstarken Produktivitäts-Laptops für 800 US-Dollar
der Laptop eine Betriebsdauer von bis zu 24 Stunden bei WLAN-Nutzung und etwa 20 Stunden bei lokaler Videowiedergabe. Zudem unterstützt es 100-W-PD-GaN-Schnellladen, wobei eine 10-minütige Aufladung für effiziente Produktivität unterwegs sorgt.Was das Display und das Design betrifft, verfügt
More news about: GEEKOM
Jun 08, 2026, 07:00 ET Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development
evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developed by AstraZeneca pursuant to an exclusive license
More news about: Compugen Ltd.
Jun 08, 2026, 05:00 ET Foresee's Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2a Platform Trial
"The role of ALDH2 in the pathophysiology of PD and other neurological diseases is quite compelling when looking at the current body of data. We are confident the results from this study will provide a strong foundation for further development in PD and other CNS diseases as this study will provide
More news about: Foresee Pharmaceuticals Co., Ltd.
Jun 07, 2026, 20:00 ET Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using
More news about: Antengene Corporation Limited
Jun 05, 2026, 09:00 ET Diakonos Oncology Shares Updated DOC1021 GBM Survival Data and Unveils Melanoma Clinical Study at ASCO 2026
immune memory.DOC1021 is now also enrolling in a refractory melanoma clinical study, targeting a population with limited options after anti-PD-1 failure.HOUSTON, June 5, 2026 /PRNewswire/ --
More news about: Diakonos Oncology
Jun 04, 2026, 17:31 ET The Inner Circle acknowledges Cha-Mei Tang as a Pinnacle Professional Member Inner Circle of Excellence
(3) provide companion diagnostics - not requiring tissue, (4) monitor biomarker expression or change of biomarker – example: change of PD-L1 expression on the tumor. PD-L1 expression predicts treatment response of immunotherapy, (5) detect cancer recurrence and minimal residual disease (MRD), and (6) deliver
More news about: The Inner Circle
Jun 04, 2026, 12:00 ET Kinefinity Vista Full-Frame 6K Digital Cinema Camera Announced; More Info at B&H Photo
be used to export video directly from the internal SSD or as a webcam for an iPhone, Mac, or PC host. Either of these ports can provide a 5V, 2A, non-PD output for powering a Kinefinity EAGLE e-viewfinder or mobile device. The Vista can be powered via its two-pin LEMO power input or by using
More news about: B&H Photo